Plague - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Plague - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Plague - Pipeline Review, H1 2016', provides an overview of the Plague pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plague and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Plague
- The report reviews pipeline therapeutics for Plague by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Plague therapeutics and enlists all their major and minor projects
- The report assesses Plague therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Plague

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Plague
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Plague Overview 8
Therapeutics Development 9
Pipeline Products for Plague - Overview 9
Pipeline Products for Plague - Comparative Analysis 10
Plague - Therapeutics under Development by Companies 11
Plague - Therapeutics under Investigation by Universities/Institutes 12
Plague - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Plague - Products under Development by Companies 16
Plague - Products under Investigation by Universities/Institutes 17
Plague - Companies Involved in Therapeutics Development 18
Aradigm Corporation 18
AvidBiotics Corp. 19
Grifols, S.A. 20
iBio, Inc. 21
Mucosis B.V. 22
Syntiron LLC 23
Takeda Pharmaceutical Company Limited 24
Tetraphase Pharmaceuticals Inc. 25
Plague - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(plague + small pox) vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
anthrax + plague vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ARD-3100 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ciprofloxacin hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
plague vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
plague vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
plague vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
plague vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
plague vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
plague vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
plague vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
plague vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
plague vaccine 2 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
pneumonic plaque vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Recombinant Protein for Pneumonic Plague - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TP-271 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Yersinia pestis vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Plague - Recent Pipeline Updates 56
Plague - Dormant Projects 60
Plague - Discontinued Products 61
Plague - Product Development Milestones 62
Featured News & Press Releases 62
Mar 30, 2015: iBio European Plague Vaccine Patent Emerges From Opposition Period 62
Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague 62
May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables

Number of Products under Development for Plague, H1 2016 9
Number of Products under Development for Plague - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Comparative Analysis by Unknown Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Plague - Pipeline by Aradigm Corporation, H1 2016 18
Plague - Pipeline by AvidBiotics Corp., H1 2016 19
Plague - Pipeline by Grifols, S.A., H1 2016 20
Plague - Pipeline by iBio, Inc., H1 2016 21
Plague - Pipeline by Mucosis B.V., H1 2016 22
Plague - Pipeline by Syntiron LLC, H1 2016 23
Plague - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 24
Plague - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Assessment by Combination Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Plague Therapeutics - Recent Pipeline Updates, H1 2016 56
Plague - Dormant Projects, H1 2016 60
Plague - Discontinued Products, H1 2016 61